NCT06532578View on ClinicalTrials.gov

Evaluate the Safety and Efficacy of CPX101 in Overweight and Obese Subjects Without Diabetes Mellitus

PHASE2RecruitingINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

August 13, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

March 31, 2026

Conditions
Overweight and Obesity
Interventions
BIOLOGICAL

CPX101 or placebo 120mg Q2W

Subcutaneous injection of CPX101 or placebo

BIOLOGICAL

CPX101 or placebo 160mg Q4W

Subcutaneous injection of CPX101 or placebo

BIOLOGICAL

CPX101 or placebo 160mg Q2W

Subcutaneous injection of CPX101 or placebo

BIOLOGICAL

CPX101 or placebo 240mg Q4W

Subcutaneous injection of CPX101 or placebo

BIOLOGICAL

CPX101 or placebo 240mg Q2W

Subcutaneous injection of CPX101 or placebo

BIOLOGICAL

CPX101 or placebo 360mg Q2W

CPX101 or placebo 360mg Q2W

BIOLOGICAL

CPX101 or placebo 360mg Q4W

CPX101 or placebo 360mg Q4W

Trial Locations (1)

Unknown

RECRUITING

Paratus Clinical Research, Chatswood

All Listed Sponsors
lead

Guangzhou Chia Tai Innovative Pharmaceutical Co., Ltd.

INDUSTRY